Exhibit 99.2
Fitters Unaudited Balance Sheet as of
| June 30, 2025 | June 30, 2024 | |||||||
| (in thousands) | ||||||||
| Current Assets | ||||||||
| Cash and cash equivalents | $ | 849 | $ | 301 | ||||
| Inventories | 1,593 | 1,363 | ||||||
| Accounts receivables | 1,364 | 1,952 | ||||||
| Deferred Tax | 75 | 26 | ||||||
| Prepaid & other current assets | 1,048 | 819 | ||||||
| 4,930 | 4,461 | |||||||
| Investments And Other Assets | ||||||||
| Property, plant and equipment, net | 107 | 110 | ||||||
| ROU Asset | 429 | 409 | ||||||
| Investment assets | 72 | 69 | ||||||
| 608 | 587 | |||||||
| Total Assets | $ | 5,538 | $ | 5,049 | ||||
| Current Liabilities | ||||||||
| Trade payables | $ | 1,025 | $ | 725 | ||||
| Accrued and other current liabilities | 11 | 126 | ||||||
| 1,037 | 851 | |||||||
| Non-current Liabilities | ||||||||
| Lease liability | ||||||||
| Deferred income tax liability | ||||||||
| - | - | |||||||
| Stockholders Equity | ||||||||
| Common Stock | 667 | 636 | ||||||
| Preferred Stock | ||||||||
| Additional paid-in capital | - | - | ||||||
| Accummulated other comprehensive loss | - | - | ||||||
| Accummulated deficit | 3,835 | 3,562 | ||||||
| Total Stockholders' Equity | 4,501 | 4,198 | ||||||
| Total liabilities and stockholders' equity | $ | 5,538 | $ | 5,049 | ||||
Fitters Unaudited Statement of Operations for the Three Months Ended
| June 30, 2025 | June 30, 2024 | |||||||
| (in thousands) | ||||||||
| Revenues | ||||||||
| Sales Revenue | $ | 501 | $ | 365 | ||||
| Clinical Trial Supply | ||||||||
| Revenues | 501 | 365 | ||||||
| Cost of Sales | 415 | 294 | ||||||
| General & administrative | 109 | 119 | ||||||
| Research and development | ||||||||
| Operating Loss | (22 | ) | (48 | ) | ||||
| Other income (expense), net | 70 | 57 | ||||||
| Loss before taxes | 47 | 9 | ||||||
| Income tax benefit | ||||||||
| Income tax expense | ||||||||
| Net loss | $ | 47 | $ | 9 | ||||
| Basic and diluted earnings per common share: | ||||||||
| Net loss per share, continuing operations – basic and diluted | $ | 0.02 | $ | 0.00 | ||||
| Weighted average common shares outstanding - basic & diluted | 3,000,000 | 3,000,000 | ||||||